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Despite the fact that seizures are commonly associated with autism spectrum disorder
(ASD), the effectiveness of treatments for seizures has not been well studied in individu-
als with ASD. This manuscript reviews both traditional and novel treatments for seizures
associated with ASD. Studies were selected by systematically searching major electronic
databases and by a panel of experts that treat ASD individuals. Only a few anti-epileptic
drugs (AEDs) have undergone carefully controlled trials in ASD, but these trials examined
outcomes other than seizures. Several lines of evidence point to valproate, lamotrigine, and
levetiracetam as the most effective and tolerable AEDs for individuals with ASD. Limited
evidence supports the use of traditional non-AED treatments, such as the ketogenic and
modified Atkins diet, multiple subpial transections, immunomodulation, and neurofeedback
treatments. Although specific treatments may be more appropriate for specific genetic and
metabolic syndromes associated with ASD and seizures, there are few studies which have
documented the effectiveness of treatments for seizures for specific syndromes. Limited
evidence supports L-carnitine, multivitamins, and N -acetyl-L-cysteine in mitochondrial dis-
ease and dysfunction, folinic acid in cerebral folate abnormalities and early treatment with
vigabatrin in tuberous sclerosis complex. Finally, there is limited evidence for a number of
novel treatments, particularly magnesium with pyridoxine, omega-3 fatty acids, the gluten-
free casein-free diet, and low-frequency repetitive transcranial magnetic simulation. Zinc
and L-carnosine are potential novel treatments supported by basic research but not clinical
studies.This review demonstrates the wide variety of treatments used to treat seizures in
individuals with ASD as well as the striking lack of clinical trials performed to support the
use of these treatments. Additional studies concerning these treatments for controlling
seizures in individuals with ASD are warranted.
Keywords: anti-epileptic drugs, autism spectrum disorder, epilepsy, gluten-free casein-free diet, ketogenic diet,
seizures, treatment
Abbreviations: 5MTHF, 5-methyltetrahydrofolate; AEDs, anti-epileptic drugs;
AER, autistic epileptiform regression; ASD, autism spectrum disorder; BR, bench
research; Ca, calcium; DBPC, double-blind placebo-controlled; PD, possibly detri-
mental; DMG, dimethylglycine; EEG, electroencephalogram; FRα, folate-receptor
alpha; GABA, γ-aminobutyric acid; GFCF, gluten-free casein-free; GOR, grade of
recommendation; HEADD, hypotonia, epilepsy, autism, and developmental delay;
IVIG, intravenous immunoglobulin; KD, ketogenic diet; MAD, modified Atkins
diet; MD, mitochondrial disease; MEG, magnetoencephalography; Mg, magne-
sium; MgSO4, Mg sulfate; MST, multiple subpial transections; N, no studies; NE,
neutral effect; rTMS, repetitive transcranial magnetic stimulation; SC, single case
report or series; TSC, tuberous sclerosis complex; VNS, vagal nerve stimulator; Zn,
zinc.
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INTRODUCTION
A number of studies suggest that seizures affect a high propor-
tion of children with autism spectrum disorder (ASD). Indeed,
the reported prevalence of epilepsy in ASD ranges from 5 to 38%,
which is clearly higher than the 1–2% prevalence in the general
childhood population (1–5). A recent larger cross-sectional study
suggests that the prevalence of epilepsy is 12.5% in children with
ASD aged 2–17 years with this prevalence clearly highest for ado-
lescents (6). In addition, the prevalence of treatment-resistant
epilepsy in children with ASD is believed to be higher than in
the general childhood population (7). Interestingly, recent reviews
note shared cognitive symptoms in epilepsy and ASD, suggest a
common etiopathophysiology (8), especially when ASD co-exists
with intellectual disability (9). The overlap between ASD and
epilepsy is also supported by studies that suggest treatment with
anti-epileptic drugs (AEDs) in children with ASD can improve
core and associated ASD symptoms.
Despite the fact that individuals with ASD and seizures appear
to represent a large ASD subgroup, traditional seizure treatments
for individuals with ASD have not been systematically reviewed
and potential novel therapies have not been discussed. Although
the first-line treatment for any child with seizures is AED ther-
apy, the poor efficacy and/or adverse effects of AED treatments in
individuals with ASD may prompt the use of traditional non-
AED or novel treatments. Additionally, since seizures in ASD
are associated with specific genetic and metabolic syndromes,
therapies that target these syndromes may augment traditional
treatments.
This review has three main purposes. First, in order to deter-
mine which traditional treatments for seizures are most effective
and well tolerated in individuals with ASD, the evidence for the
effectiveness of traditional seizure treatments is reviewed (see Tra-
ditional Treatments). Second, since seizures in ASD are associated
with specific genetic and metabolic syndromes, therapies that tar-
get these syndromes are reviewed as they may augment traditional
treatments (see Treatments for Specific Syndromes). Third, since
there is a high prevalence of the use of novel treatments in ASD
individuals with and without seizures (10) and in the general
ASD population (11), novel treatments that have the potential
to improve seizures are reviewed (see Novel Treatments). Overall,
this review is designed to provide a comprehensive overview of the
treatments for individuals with ASD who have comorbid seizures
in order to achieve optimal outcomes.
METHODS
The Problem-Intervention-Comparison-Outcomes (PICOs) frame-
work was used to conduct this review (12). The goal was to identify
research studies which reported treatments that have the poten-
tial to improve clinical seizures for: (a) individuals with ASD and
seizures, or (b) individuals with genetic and/or metabolic syn-
dromes in which ASD and seizures are prominent features. We
did not compare these treatments to other treatments and we
considered all study designs. Our primary goal was to consider
improvement in clinical seizure severity as the primary outcome.
Since many treatments for children with ASD, especially seizure
treatments, can have effects on core and associated ASD symptoms,
as well as adverse effects (10), we also considered, as a secondary
outcome, the effect of these treatments on core and associated ASD
symptoms.
IDENTIFICATION OF POTENTIAL TREATMENTS
Potential treatments for seizures in individuals with ASD were
identified in several ways. First, we searched standard scientific
databases. Second,we considered treatments associated with meta-
bolic and genetic disorders that are commonly found in children
with ASD and seizures. Third, we considered novel treatments
obtained from two sources: (a) a panel of experts who regularly
treat children with ASD and who attended at least one of the three
Elias Tembenis Seizure Think Tanks (13), and (b) recent surveys
of novel treatments used by parents in children with ASD and
seizures and in the general ASD population (10, 11).
SEARCH STRATEGY
A prospective protocol for this systematic review was developed
a priori, and the search terms and selection criteria were chosen in
an attempt to capture all pertinent publications. A computer-aided
search of PUBMED, Google Scholar, CINAHL, EmBase, Scopus,
and ERIC databases from inception through March 2013 was con-
ducted to identify pertinent publications using the search terms
“autism,” “autistic,” “Asperger,” “ASD,” “pervasive developmental
disorder,” and “PDD” in combination with the terms “epilepsy,”
”epileptic,” and ”seizure.” The references cited in identified pub-
lications were also searched to locate additional studies. Three
authors (Richard E. Frye, John C. Slattery, and Chrystal Lau)
screened titles and abstracts of all potentially relevant publications.
Studies were initially included if they: (a) involved individuals with
ASD and epilepsy or seizures, and (b) reported at least one treat-
ment for epilepsy or seizures. Articles were excluded if: (a) they
involved animal models which did not specifically correspond to a
well-known clinical syndrome; (b) were abstracts, posters, or con-
ference proceedings that were not published in a journal; (c) did
not present new or unique data (such as review articles or expert
option); or (d) presented duplicate data.
LEVEL OF EVIDENCE RATINGS
Although we considered conducting a meta-analysis on identi-
fied treatments, the lack of standard outcomes and the limitations
in study design prevented a meta-analysis of any identified treat-
ment. As an alternative, we provide a grade of recommendation
(GOR) for each treatment based on the level of evidence. Using
a well-established scale (14), each study was individually assessed
to determine the level of evidence, ranging from Level 1 to 5 (see
Table 1). After assessing all identified studies for each treatment, a
GOR ranging from A (solid evidence) to D (limited, inconsistent,
or inconclusive evidence) was assigned (see Table 2). Since a treat-
ment could be a GOR of D for several reasons, we specified if the
treatment received this rating because the evidence was a single
case report or series (SC), was only based on bench research (BR),
demonstrated a neutral effect (NE), or was found to be possibly
detrimental (PD). If no studies were identified for a treatment, a
GOR of N (no studies) was assigned.
DATA ANALYSIS AND SYNTHESIS
We summarized and synthesized the information about the var-
ious treatments in several ways. First, a GOR for: (a) treating
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Table 1 | Levels of evidence.
Level Description
1a SR or meta-analysis of RCTs with homogeneity or Cochrane
review with favorable findings
1b Prospective high-quality RCT
2a SR of cohort (prospective, non-randomized) studies with
homogeneity
2b Individual cohort (prospective, non-randomized) study or
low-quality RCT
3a SR of case-control (retrospective) studies with homogeneity
3b Individual case-control (retrospective) study
4 Case series or reports
5 Expert opinion without critical appraisal or based on physiology or
bench research
RCT, randomized controlled trial; SR, systematic review.
Table 2 | Grade of recommendation.
Grade Description
A At least one Level 1a study or two Level 1b studies
B At least one Level 1b, 2a, or 3a study, or two Level 2b or 3b studies
C At least one Level 2b or 3b study, or two Level 4 studies
D Level 5 evidence, or troublingly inconsistent or inconclusive
studies of any level, or studies reporting no improvements
N No studies identified
behavioral and cognitive symptoms associated with ASD, (b) treat-
ing epilepsy in general, and (c) treating individuals with ASD and
epilepsy, is provided in Table 3 for each treatment as well as impor-
tant adverse effects. Also included in Table 3 is the percentage of
parents reporting the use of specific treatments for children with
and without seizures as reported in a recent survey study (10).
A detailed discussion of the studies as well as the derivation of
the ratings is discussed through Sections “Traditional Treatments,”
“Treatments for Specific Syndromes,”and“Novel Treatments.”Sec-
ond, using the available evidence, we provide recommendations
for treatments for children with ASD and epilepsy (see Sum-
mary). Third, we discuss treatments that may have potential for
future research study (see Summary). Fourth, a critique of the
strengths and weakness of the studies on treatments for epilepsy
in individuals with ASD is provided (see Summary).
TRADITIONAL TREATMENTS
ANTI-EPILEPTIC DRUGS
Effectiveness of anti-epileptic drugs in autism spectrum disorder
There were no randomized control trials, cohort studies, or sys-
tematic reviews of case-control studies for any AED focusing on
the control of seizure in the ASD population.
Two survey studies, one controlled and one uncontrolled, iden-
tified treatments used for seizures in individuals with ASD. The
first study, conducted in the early 1990s, obtained the responses
from 838 members of the Autism Society of North Carolina on
a wide range of ASD treatments (15) (Level 4). Responders listed
medications as well as their overall satisfaction with a class of drugs
in general. Overall, 15.2% of the ASD individuals were receiving
AED medications with the most common AEDs for the treatment
of epilepsy being carbamazepine, valproic acid, and phenytoin,
and the parents rated being satisfied with the AEDs in general.
The second survey study, a retrospective national case-control
survey study (Level 3b) conducted in 2010, determined whether
a wide variety of treatments, including AEDs, were more bene-
ficial than others treatments for individuals with ASD who also
had seizures and/or epilepsy. Frye et al. (10) surveyed 733 par-
ents of children with ASD who had seizures, epilepsy, and/or an
abnormal electroencephalogram (EEG) and 290 parents of chil-
dren with ASD but without these abnormalities as a control group.
Parents rated the perceived effect of traditional AED and non-AED
seizure treatments and non-traditional ASD treatments on clinical
seizures and other clinical factors including sleep, communica-
tion, behavior, attention, and mood as well as three treatment side
effects. A cluster analysis demonstrated that treatments could be
broadly categorized into AED and non-AED treatments. For chil-
dren with ASD and clinical seizures, AED treatments were found,
on average, to improve seizures but worsened other clinical fac-
tors. When the AED treatments were specifically analyzed, four
AEDs, specifically valproate, lamotrigine, levetiracetam, and etho-
suximide, were found to provide the best seizure control and at the
same time worsen other clinical factors the least out of all AEDs
examined (see Figure 1). The other AEDs examined included
phenytoin, clonazepam, carbamazepine, oxcarbazepine, topira-
mate, gabapentin, zonisamide, felbamate, and phenobarbital. All
these other AEDs except phenobarbital were rated as significantly
less beneficial for controlling seizures with a less favorable effect
on other clinical factors, while phenobarbital was rated as having
the most unfavorable effect on other clinical factors.
In a case series (Level 4) of 66 children with epilepsy, 50 with
ASD, and 16 with ASD-like symptoms, performed in 1991, Gilbert
reported a high response rate (with a low adverse effect rate) for
valproate, carbamazepine, and ethosuximide (16). In another case
series (Level 4) of 50 children, 28% with ASD, lamotrigine was
found to have a favorable effect on seizures, particular in partial
complex and absence seizures with a less favorable effect on tonic,
tonic-clonic, and myoclonic seizures (17). Smaller case reports and
case series (Level 4) have reported improvements in seizure fre-
quency in children and adolescents with ASD using carbamazepine
(18–20) and lamotrigine (17). Thus, there are many lower-quality
(Level 4 and 3b) studies supporting the use of valproate, lam-
otrigine, levetiracetam, ethosuximide, and carbamazepine for the
control of seizures in individuals with ASD, leading to a GOR of
C for these AEDs. Other AEDs such as phenytoin, clonazepam,
oxcarbazepine, topiramate, gabapentin, and phenobarbital, which
are not uncommonly prescribed to children with ASD, do not have
similar support in the literature and receive a GOR of N.
A recent systematic review of AED efficacy and effectiveness
as initial monotherapy for epileptic seizures in children has been
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Table 3 | Seizures treatments for autism spectrum disorder.
Treatment Grade of recommendation Prevalence of use Important adverse effects
Seizures Behavioral
and cognitive
ASD symptoms
ASD
with
seizures
Behavioral
and cognitive
ASD symptoms
ASD
with
seizures
TRADITIONALTREATMENTS
Valproate B A C 6% 39% Weight gain (occasional), alopecia, carnitine depletion
(infrequent); hepatotoxicity, abnormal liver function
tests, hyperammonemia, and pancreatitis (rare)
Lamotrigine C D – NE C 3% 27% Stevens–Johnson reaction, abnormal liver function
tests, aseptic meningitis (rare)
Levetiracetam C D – NE C 1% 23% Agitation and mood instability (infrequent)
Ethosuximide B D – NE C <1% 4% Weight loss (occasional), gingival hyperplasia
(infrequent)
Carbamazepine B D – SC C 1% 26% Dizziness, ataxia, nausea (occasional), hyponatremia,
photosensitivity (rare)
Topiramate B D – PD N 1% 25% Weight loss, cognitive dysfunction, somnolence,
agitation (occasional), metabolic acidosis,
nephrolithiasis, glaucoma (rare)
Clonazepam C D – PD N 3% 16% Drowsiness, ataxia, cognitive dysfunction
(occasional), abnormal liver function tests, respiratory
depression (rare)
Oxcarbazepine B N N 2% 22% Dizziness, ataxia, nausea (occasional), hyponatremia,
photosensitivity (rare)
Phenobarbital B D – PD N 2% 13% Drowsiness, lethargy, hyperactivity (common)
Phenytoin B D – PD N 1% 14% Dizziness, ataxia, nausea (occasional), abnormal liver
function tests, gingival hyperplasia (infrequent)
Gabapentin C N N 1% 8% Weight gain, drowsiness, ataxia, cognitive dysfunction
(occasional), edema (infrequent)
KD B B C 0% 7% Constipation, weight loss (occasional), nausea
(infrequent), acidosis, nephrolithiasis (rare)
MAD C C C 1% 3% Constipation, slow weight gain (occasional), nausea
(infrequent)
VNS B D – NE D – NE 0% 4% Hoarseness, throat discomfort (infrequent), shortness
of breath, aspiration (rare)
Surgery – resec-
tion
C D – PD C 0% <1% Cognitive and motor dysfunction (occasional),
intracranial hemorrhage (infrequent), intracranial
infection (rare)
Multiple subpial
transections
C C C Cognitive and motor dysfunction, intracranial
hemorrhage (infrequent), intracranial infection (rare)
Steroids C D – SC D – SC 21% 5% Hyperglycemia, hypertension, edema, poor wound
healing, weakness, emotional dysregulation, weight
gain, nausea, insomnia, gastrointestinal ulcer
(occasional)
(Continued)
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Table 3 | Continued
Treatment Grade of recommendation Prevalence of use Important adverse effects
Seizures Behavioral
and cognitive
ASD symptoms
ASD
with
seizures
Behavioral
and cognitive
ASD symptoms
ASD
with
seizures
IVIG C C N 1% 3% Fever, nausea, rash (occasional), aseptic meningitis
(rare)
Neurofeedback B B C <1% <1% None reported
SPECIFIC SYNDROME ANDTREATMENTS
Tuberous sclerosis complex
Vigabatrin B C C 0% <1% Retinal degeneration and central visual loss
(infrequent)
Fragile X
AEDs C N N Various (see above)
Mitochondrial disease
L-carnitine/acetyl-
L-carnitine
N B N 22% 18% Abdominal discomfort, diarrhea, irritability (infrequent)
Multivitamins N B N 16% 12% Aggression, inattention, nausea (infrequent)
N -acetyl-L-
cysteine
N B N Abdominal discomfort, diarrhea, nausea (occasional)
Cerebral folate deficiency
Folinic acid C C C Hyperactivity, aggression (rare)
Milk-free diet N C N Hypocalcemia (rare)
Urea cycle disorders
Low-protein diet/
ammonia binders/
amino acid
supplementation
B C N None reported
Succinic semialdehyde dehydrogenase deficiency
Vigabatrin D – NE D – NE D – NE Retinal degeneration and central visual loss
(infrequent)
Creatine deficiency syndromes
Creatine
monohydrate
C C C None reported
Biotinidase deficiency
Biotin D – NE D – NE D – NE None reported
Smith–Lemli–Opitz syndrome
Cholesterol N B N None reported
Branched-chain ketoacid dehydrogenase kinase deficiency
BCAA
supplement
D – PD D – NE D – NE None reported
Pyridoxine-dependent and responsive seizures
Pyridoxine C B D – SC 27% 15% Irritability, hyperactivity (uncommon)
Cobalamin metabolism
Cobalamin C C N 32% 20% Irritability, hyperactivity (uncommon)
Organic aciduria – D-glyceric aciduria
Fructose
restriction
N D – SC D – SC None reported
(Continued)
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Table 3 | Continued
Treatment Grade of recommendation Prevalence of use Important adverse effects
Seizures Behavioral
and cognitive
ASD symptoms
ASD
with
seizures
Behavioral
and cognitive
ASD symptoms
ASD
with
seizures
NOVELTREATMENTS
Magnesium (Mg) A D – NE N 26% 17% Abdominal discomfort, diarrhea, nausea (infrequent)
Pyridoxine and
Mg
N B N Abdominal discomfort, diarrhea, nausea, irritability,
hyperactivity (infrequent)
Zinc D – BR N N Abdominal discomfort, diarrhea, nausea (infrequent)
Dimethylglycine D – NE D – NE N 14% 9% None reported
Taurine D – PD N N 10% 10% None reported
L-Carnosine D – BR C N 5% 5% Hyperactivity (infrequent)
Omega-3 fatty
acids
C B N Abdominal discomfort, diarrhea, nausea (infrequent),
abnormal liver function tests (rare)
Homeopathy N D – PD N None reported
Gluten-free
casein-free diet
N B C 41% 25% None reported
Feingold/elimination
diet
D – SC N N None reported
Slow repetitive
transcranial
magnetic
stimulation
B B N <1% <1% Headache (occasional)
EO, Expert Opinion; NE, Neutral Effect / Inconsistent; PD, Possibly Detrimental; SC, Single Case Report or Series; BR, Based on bench research.
FIGURE 1 | Seizure survey rating for the most favorable rated
anti-epileptic drug treatments for clinical seizures. The perceived effect
on seizures was not different across the four anti-epileptic drug
treatments. Out of the four treatments lamotrigine appeared to worsen
several other clinical factors, such as communication, attention, and mood
less than valproate.
conducted by International League Against Epilepsy (21). Interest-
ingly, many AEDs do not have well-controlled studies to support
their use as monotherapy in children although stronger evidence is
found for their use in adults with epilepsy. The ratings presented in
Table 3 for these AEDs were abstracted from this systematic review.
All AEDs except levetiracetam, ethosuximide, and gabapentin were
abstracted from data on partial onset seizures in children. For
levetiracetam, ethosuximide, and gabapentin there was no data on
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partial onset seizures in children so data from their efficacy for
absence seizures in children was used.
Cognitive and behavioral effects of anti-epileptic drugs in autism
spectrum disorder
Studies that have examined the behavioral and cognitive effects of
AEDs in ASD are reviewed in this section.
Valproate. In randomized, prospective, double-blind, placebo-
controlled (DBPC) studies (Level 1b), valproate monotherapy
reduced repetitive behaviors (22) and irritability (23, 24) in indi-
viduals with ASD. In contrast, in an 8-week randomized, prospec-
tive, DBPC study (Level 1b) of aggressive ASD patients, improve-
ments in irritability, aggression, or general clinical status were
not different between the valproate treated and placebo groups
(25), but many of the subjects maintained a sustained response
to valproate in an open-label extension, and the participants who
were weaned off valproate demonstrated relapse of symptoms.
Thus, the researchers suggested that a large placebo response pre-
vented them from ruling-out a true valproate effect. This study
was complicated by the fact that the majority of the children had a
significant intellectual impairment, children were excluded if they
had a previous positive response to valproate, and children were
tapered off all other psychotropic and anti-epileptic medication
just prior to entering the trial.
Valproate has also been reported to improve behavioral and
core ASD symptoms in a case series (Level 4) of ASD children
with and without epilepsy (26) and to substantially improve ASD
symptoms in case reports and series (Level 4) of children with
subclinical epileptic-like discharges on EEG (27–32). In a case
series (Level 4) of children with ASD or ASD-like symptoms and
epilepsy, Gilbert reported that 41% treated with valproate demon-
strated positive psychotropic effects (16). These studies provide
good evidence that valproate can have beneficial cognitive and
behavioral effects in individual with ASD. Given that at least two
Level 1b studies have demonstrated positive effects and that these
findings are supported by several additional studies, valproate is
receives a GOR of A for the treatment of cognitive and behavioral
symptoms in ASD.
Levetiracetam. In a prospective, open-label trial (Level 2b), lev-
etiracetam improved attention, hyperactivity, emotional lability,
and aggressive behaviors in six drug-naïve boys but not in four
boys who had been recently weaned off psychotropic medications
(33). However, no significant improvement or worsening of aber-
rant or repetitive behaviors or impulsivity or hyperactivity was
found in a small prospective, randomized, DBPC trial (Level 2b)
of levetiracetam (34). Thus, there is insufficient evidence to sug-
gest that levetiracetam improves behavioral or cognitive features of
ASD; however, these studies suggest that levetiracetam is well tol-
erated without detrimental cognitive or behavioral effects. Thus,
levetiracetam is given a GOR of D – NE for neutral effect on ASD
cognitive and behavioral symptoms.
Lamotrigine. Lamotrigine did not improve or worsen aberrant
or ASD behaviors in a small prospective, randomized, DBPC study
(Level 2b) (35) but in a case series (Level 4) of 50 children,
28% with ASD, parents reported improvements with lamotrigine
in cognitive and ASD symptoms in 62% of children with ASD
who had intractable epilepsy, even if seizure frequency did not
improve (17). Although lamotrigine may be cognitively enhancing
in non-ASD epileptic individuals (36) and is efficacious for mood
stabilization in bipolar disorder (37), there is insufficient evidence
to suggests that it improves behavioral or cognitive features of
ASD; rather these studies suggest that lamotrigine has few detri-
mental cognitive or behavioral effects in individuals with ASD.
Thus, lamotrigine is given a GOR of D – NE for neutral effect on
cognitive and behavioral symptoms in individuals with ASD.
Topiramate. In individuals with ASD, topiramate, when added
on to risperidone, reduced irritability, stereotypical behavior, and
hyperactivity in a DBPC study (Level 2b) (38) but caused behav-
ioral adverse effects in some participants in an open-label study
(Level 4) (39). Given the inconsistent results and the fact that topi-
ramate can have neurocognitive adverse effects in individuals with
epilepsy (40), topiramate is probably only helpful for the treatment
of behavior in selected individuals with ASD. Thus, topiramate is
given a GOR of D – PD for possible detrimental effect on cognitive
and behavioral symptoms in children with ASD.
Other AEDs. In a case series (Level 4) of children with ASD
or ASD-like symptoms and epilepsy, Gilbert reported that 56%
treated with carbamazepine demonstrated positive psychotropic
effects (16). Thus, carbamazepine receives a GOR of D – SC for
because the evidence is limited to a single case-series. In a retro-
spective case-control survey study (Level 3b) ethosuximide was
rated by parents to be one of four AEDs that had the least detri-
mental effect on behavioral and cognition but there was no ratings
of improvements in cognitive or behavioral symptoms (10). Thus,
ethosuximide receives a GOR of D – NE for a neutral effect on
behavioral and cognition in ASD.
In a case series (Level 4) of 66 children with epilepsy, 50
with ASD, and 16 with ASD-like symptoms, Gilbert reported a
high prevalence of extremely negative behavioral adverse effects
for clonazepam, phenytoin, phenobarbital, and nitrazepam (16).
Given that phenytoin, clonazepam, and phenobarbital were in the
group of AEDs rated as having detrimental behavioral and cogni-
tive effects on children with ASD in a retrospective case-control
survey study (Level 3b) (10), these AEDs receive a GOR of D –
PD for possible being detrimental for behavioral and cognitive
symptoms of ASD.
TRADITIONAL NON-ANTI-EPILEPTIC DRUG TREATMENTS
Ketogenic and modified Atkin’s diet
The ketogenic diet (KD) has a long and successful history for
treating epilepsy, especially for AED refractory epilepsy, and
some researchers have suggested it as a first-line therapy. Several
unblinded but randomized controlled trials (Level 2b) conducted
in children with seizures have reported an effect comparable to
AEDs (41), resulting in a GOR of B for the treatment of seizures.
Since long-term compliance with the KD can be difficult because
of the very high levels of fat (90% of calories), the modified Atkins
diet (MAD) is sometimes used since it may have better long-term
patient compliance. Studies on children and adults with epilepsy
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suggest similar efficacy with the KD and MAD (Level 2b) (42),
resulting in a GOR of C for the MAD for seizure control. In a
retrospective case-control survey study (Level 3b), the KD was
rated as being the most favorable non-AED treatment for improv-
ing seizures, and also was rated as providing favorable effects on
other important clinical factors related to ASD (Figure 2) (10).
In addition, a small prospective, uncontrolled study demonstrated
a favorable response rate for the improvement of ASD symptoms
(Level 2b) (43). Another recent case report (Level 4) demonstrated
that the KD significantly improved seizures in a 12-year-old girl
with ASD (44). Thus the KD receives a GOR of B for treatment of
ASD cognitive and behavior symptoms and GOR of C for treat-
ment of epilepsy in individuals with ASD. The MAD also received
favorable ratings in the retrospective case-control survey study
(Level 3b) for the control of seizures and other behavioral and cog-
nitive ASD symptoms, although not as favorable as the KD (10).
Thus, the MAD receives a GOR of C for the treatment of behavioral
and cognitive ASD symptoms and for controlling seizures in indi-
viduals with ASD. Overall these are promising interventions for the
treatment of seizures in individuals with ASD, especially in those
with drug-resistant seizures. More research is clearly warranted.
Vagus nerve stimulator
In adults and adolescents with drug-resistant epilepsy, the vagal
nerve stimulator (VNS) has been shown to reduce seizure fre-
quency in randomized controlled studies (Level 2b) (45), resulting
in a GOR of B for seizure control. A retrospective review of 59
ASD patients with seizures who were treated with VNS found that
more than half experienced at least a 50% reduction in seizure fre-
quency, and more than half demonstrated significant quality of life
improvements (Level 4) (46). The VNS was reported to improve
seizures and behavior in an adult with Asperger syndrome and
bitemporal epilepsy (Level 4) (47). However, a prospective trial of
eight children and adolescents with medically intractable epilepsy
and ASD found no improvement in seizure frequency or cognition,
and less than half of the cases demonstrated minor improvements
in general functioning (Level 2b) (48). Lastly, in a case series, only
two of nine patients with treatment-resistant epilepsy and ASD
demonstrated limited improvement with the VNS (Level 4) (49).
Given these conflicting results, the VNS receives a GOR of D – NE
for neutral effect for the treatment of seizures and cognitive and
behavior symptoms in individuals with ASD. Given the fact that
the VNS requires operative placement which could lead to com-
plications, it is probably wise to carefully consider VNS treatment
in children with ASD and treatment-resistant epilepsy after other
epilepsy treatments have failed.
Surgery
In general, the most efficacious routine epilepsy surgery involves
resection of a cortical area in which epileptic foci clearly arises.
Straightforward situations occur where potential epileptic foci are
clearly visualized on magnetic resonance imaging, such as Tuber-
ous Sclerosis Complex (TSC) and tumors, particularly temporal
lobe tumors (50–52). However, even when a focus is visualized, it is
essential to verify the epileptic focus. For individuals without mag-
netic resonance imaging-confirmed foci, procedures for localizing
epileptic foci, such as magnetoencephalography (MEG), subdural
intracranial recording grids, and/or intraoperative mapping, are
necessary. Given the difficulty with performing blinded or case-
control studies in a surgical population, systematic reviews have
examined many case series (Level 4) of outcomes from lesional
surgery (53). Thus, epilepsy surgery in general is given a GOR of
C because of multiple Level 4 studies documenting effectiveness.
Several case series have examined whether ASD symptoms and
cognition change after epilepsy surgery in children with ASD and
treatment-resistant epilepsy. Of five children with resection of
focal lesions, improvement could only be confirmed by neuropsy-
chological testing in one case and another child clearly became
worse (Level 4) (54). In a case series of two boys with focal epilepsy
and TSC-like lesions, only one child was clearly improved but only
years after the surgery (Level 4) (55). In a series of 24 epilepsy
surgery cases, none of the 7 children with ASD had a change in their
ASD diagnosis or demonstrated an improvement in intelligence
(Level 4) (56). In another case series of 60 children, 38% who had
ASD, temporal lobe resection to control seizures did not result in
an overall change in psychiatric diagnosis (Level 4) (57). However,
FIGURE 2 | Seizure survey ratings for the most favorably rated
non-anti-epileptic drug treatments for clinical seizures. The
ketogenic diet was perceived to improve seizures more than the
gluten-free-casein-free diet and hyperbaric oxygen treatment. Other
clinical factors were not perceived to differ significantly between these
four treatments except for behavior, sleep and mood, which was
significantly better for the gluten-free casein-free diet as compared to
some other treatments.
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in another case series of 16 patients, 5 who had ASD, 3 of these
ASD patients demonstrated a positive behavioral change, whereas
1 ASD patient demonstrated no change, and another 1 worsened
(Level 4) (58). Thus, there are several Level 4 studies demonstrating
that standard epilepsy surgery (i.e., resection) does not consistently
improve ASD symptoms or cognition and can result in worsening
of behavioral and cognitive outcomes, thus such surgery receives
a GOR of D – PD for being potentially detrimental.
In some children with autistic epileptiform regression (AER),
multiple subpial transections (MSTs) have been studied (59–61)
but this type of surgery is not common. Favorable results have been
reported in two children with AER after MST (Level 4) (59) but a
slightly larger case-series suggests that any improvement is limited
and temporary (Level 4) (61). Impressive results from MST were
reported in a case series (Level 4) of 18 children with ASD who
underwent extensive extra- and intra-operative electrocorticogra-
phy pre-surgical workups, including MEG, to guide subdural grid
placement (Level 4) (60). Most of these cases were found to have
many independent foci, required MST in several different cortical
areas, and all children were also treated with steroids. In this series,
4, 8, and 6 children demonstrated major, moderate, and minor
improvements, respectively. None of the children demonstrated
worsening. This latter study suggests that optimal outcomes can
be obtained when MST is applied to multiple foci in combination
with steroids. MST receives a GOR of C for improving seizures
and behavioral symptoms in children with ASD, particularly the
subgroup with AER, since several case-series support this notion.
MST has been documented to be effective in seizure reduction
in children with intractable epilepsy without ASD in several case
series (Level 4) (62–64), resulting in a GOR of C.
Immunomodulatory treatments
Immunomodulatory treatments, particularly steroids and intra-
venous immunoglobulin (IVIG), have been used to treat many
drug-resistant epilepsy syndromes as well as those which are
believed to have an autoimmune basis. Such treatments are par-
ticularly useful in Landau–Kleffner syndrome and Continuous
Spike-Wave Activity during Slow-Wave Sleep, both of which are
syndromes that share some characteristics with ASD.
Despite the relatively common use of steroids in the treat-
ment of ASD (see Table 3), only two case reports (Level 4) of
children with normal EEGs and non-epileptic autistic regression
documented improvements in language and behavior following
corticosteroid treatment (65, 66). Steroid treatment has been doc-
umented to have positive effects on improvements in seizures and
EEG activity in children with ASD when used in combination
with MST in a case series of children with ASD and subclinical
epileptiform discharges (Level 4) (60) and in combination with
valproic acid in an open-label prospective study (Level 2b) (67).
Thus, for the treatment of ASD behaviors and epilepsy in individ-
uals with ASD, steroid treatment has a GOR of D – SC because of
the limited reports documenting its usefulness. Steroids have been
documented to be effective in seizure reduction in children with
intractable epilepsy without ASD in several case series (Level 4)
(68, 69), resulting in a GOR of C.
A relatively large case series (Level 4) (70) and a case series (Level
4) using a standardized treatment protocol (71) have documented
the benefit of IVIG in children with ASD without epilepsy and one
of these studies demonstrated regression with discontinuation of
IVIG treatment (70). In contrast, other smaller case series (Level
4) (72) and case series (Level 4) using non-standardized proto-
cols (73) were not able to confirm such improvements (overall
GOR of C for the treatment of ASD symptoms). Although IVIG is
not uncommonly used in drug-resistant epilepsy, the evidence for
its efficacy remains documented in case series (Level 4) (74–77)
(overall GOR of C for the treatment of seizures in general). IVIG
treatment receives a GOR of N for seizures in ASD since there are
no reports for its use in this context.
Neurofeedback
Neurofeedback is a safe treatment that uses operant condition-
ing to increase coherence between seizure prone and non-seizure
prone brain regions. Coherence information is integrated into an
auditory, visual, or audiovisual game. The patient succeeds at the
game by increasing coherence between selected brain regions (78).
Two recent meta-analyses (Level 3a) suggest that neurofeedback
can reduce seizures in a majority of patients, even in patients with
otherwise uncontrolled epilepsy (79, 80), supporting a GOR of B.
Research suggests that neurofeedback may be an effective form
of cognitive therapy for children with ASD (78) and a recent
review has outlined seven controlled studies (81) with at least three
prospective studies using a non-blind wait-list control group (82–
84) (Level 2b). Thus, the use of neurofeedback for behavioral and
cognitive symptoms of ASD receives a GOR of B for treating ASD
symptoms. Several case studies suggest that it may be helpful for
seizure disorders in ASD (Level 4) (85–87), supporting a GOR of C.
TREATMENTS FOR SPECIFIC SYNDROMES
Autism spectrum disorder is associated with several metabolic and
genetic syndromes in which at least some of the pathophysiol-
ogy is known. Some of these syndromes have treatments which
could improve the underlying pathophysiological processes and,
thus, the associated seizures. In this section, we review genetic and
metabolic disorders associated with ASD and seizures and discuss
potential treatments.
TUBEROUS SCLEROSIS COMPLEX
In one case series, vigabatrin, a γ-aminobutyric acid (GABA)
transaminase inhibitor that increases GABA concentrations in the
brain, was found to be particularly effective for infantile spasms
and partial seizures in TSC patients with ASD (Level 4) (88). Viga-
batrin also improved core ASD symptoms in some patients in
this case series (Level 4) (88). In two case series (Level 4), start-
ing vigabatrin soon after the onset of seizures lowered the risk of
developing ASD symptoms as compared to a delay in starting viga-
batrin treatment (Level 3b) (89, 90). In one case report (Level 4), a
child with TSC demonstrated AER after vigabatrin treatment was
discontinued, suggesting that continued treatment with vigabatrin
may have prevented the development of ASD (91). Since several
case series and reports have documented the potential beneficial
effect of vigabatrin for seizures, particularly infantile spasms, and
cognitive and behavioral symptoms in ASD, this treatment receives
GOR of C for both ASD symptoms and seizures, particularly when
started early in life. A small prospective, randomized, multicenter
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controlled trial (Type 1b) has demonstrated the effectiveness of
vigabatrin for infantile spasms in TSC (92), resulting in a GOR of
B for seizure control in TSC.
FRAGILE X
Fragile X, the most commonly inherited autism syndrome,
accounts for approximately 1–5% of ASD cases (93). An imbal-
ance between the excitatory metabotropic glutamate receptor and
the inhibitory GABA receptor is believed to cause many of the
behavioral, cognitive, and epileptiform symptoms in Fragile X
syndrome. Although seizures appear to frequently occur (10–20%
prevalence) in Fragile X, case series, and survey studies (Level 4)
suggest that they are usually easily treatable with standard AED
therapy (94–97). Mouse models (Level 5) have demonstrated that
novel glutamate receptor modulators, such as the inverse agonist 2-
methyl-6-(phenylethynyl) pyridine (98), as well as GABA agonists,
such as baclofen and ganaxolone (99), can increase seizure thresh-
old. Similar approaches are being used in clinical trials to treat
ASD symptoms in Fragile X patients (100). In addition, mouse
models (Level 5) have demonstrated that other novel treatments
such as lovastatin can reduce excess hippocampal protein synthe-
sis leading to reduced epileptogenesis (101) and that addressing a
central metabolic regulatory abnormality with glycogen synthase
kinase-3 inhibitors reduces seizures (102).
MITOCHONDRIAL DISEASE AND DYSFUNCTION
Mitochondrial dysfunction appears to be one of the most preva-
lent metabolic disorders in ASD (103). One of the first descriptions
of a mitochondrial disease (MD) associated with ASD was the
HEADD syndrome, an association of hypotonia, epilepsy, autism,
and developmental delay, which was described in a series of
ASD children with respiratory chain disorders (104). Seizures are
present in an estimated 41% of children with ASD and MD (103).
No treatments have been systematically studied for the treat-
ment of seizures in children who have MD with or without ASD
(105, 106). Children with ASD and MD have been treated with
a variety of MD treatments including carnitine, co-enzyme Q10,
B vitamins, and vitamins C and E (107). Certain standard treat-
ments for MD have been shown to improve core and associated
symptoms of ASD in controlled studies. Interestingly, these treat-
ments have not undergone rigorous study for the treatment for
MD and are used largely on the basis of expert opinion. Treatments
used for MD that have been studied in ASD include l-carnitine in
two DBPC studies (Level 2b) (108, 109) resulting in a GOR of B
for ASD symptoms; multivitamins containing B vitamins, antiox-
idants, vitamin E, and co-enzyme Q10 in two DBPC studies (Level
2b) (110, 111) resulting in a GOR of B for ASD symptoms; and
N -acetyl-l-cysteine in two DBPC trials (Level 2b) (112, 113) and
a case report (Level 4) (114) resulting in a GOR of B. Although
the efficacy of improving seizures with standard treatments for
MD is not known, resulting in a GOR of N for seizures, it is logi-
cal to assume that improving mitochondrial function may reduce
seizures.
ABNORMALITIES IN FOLATE METABOLISM
Folate is essential for a wide range of important metabolic
processes, including oxidative pathways, homocysteine metabo-
lism, and gene methylation (115). Disruption in any of these
processes could result in an increased susceptibility to developing
seizures. ASD has been associated with several polymorphisms that
can decrease production of 5-methyltetrahydrofolate (5MTHF)
and impair folate transport across the blood-brain barrier and
into neurons, including polymorphisms in methylenetetrahydro-
folate reductase (116–125), dihydrofolate reductase (126), and the
reduced folate carrier (117). More significant is impairment of the
transport of 5MTHF across the blood-brain barrier by dysfunction
of the folate-receptor alpha (FRα) (127). This transport system
can be blocked by the FRα autoantibody which may be present
in a majority of children with ASD (127, 128) or can be dysfunc-
tional in ASD children with MD (129). Individuals with the FRα
autoantibody are typically treated with 0.5–2 mg/kg/day of folinic
acid, while individuals with MD may require 4+mg/kg/day of
folinic acid. In addition, a milk-free diet has also been shown to
reduce serum FRα autoantibody titers in a controlled study (130).
Multiple small and large case series (Level 4) have demonstrated
that folinic-acid treatment in ASD children with FRα autoanti-
body can result in partial improvements in communication, social
interaction, attention, and stereotypical behavior (127, 130–133)
to complete recovery of ASD symptoms (132, 134), resulting in
a GOR of C for ASD symptoms. Two case series (Level 4) have
noted improvement in seizures in children with ASD and cerebral
folate abnormalities with folinic acid treatment resulting in a GOR
of C for ASD and seizures (133, 134). In several case reports and
case series (Level 4), folinic acid has been shown to treat refrac-
tory epilepsy in a disorder called folinic-acid responsive seizures
(135, 136), giving it a GOR of C for epilepsy. Interestingly, the
folinic-acid responsive seizure syndrome is now understood to
overlap with pyridoxine-responsive seizures (137). The milk-free
diet has been shown to decrease the serum concentration of the
FRα autoantibody and improve irritability in ASD in a controlled
study (Level 2b), resulting in a GOR of C for ASD symptoms. The
milk-free diet has not been studied for seizures in children with or
without ASD (GOR of N).
UREA CYCLE DISORDERS
Two cases of ASD children with urea cycle disorders, one with
ornithine transcarbamylase deficiency and arginase deficiency
(138) and another with carbamoyl phosphate synthetase defi-
ciency (139) have been reported to date. Standard therapy is
focused on reducing ammonia through a low-protein diet and
ammonia binders as well as supplementation with specific amino
acids and various vitamin supplements (140). Improvement in
ASD symptoms has been reported with treatment in these case
reports (Level 4), resulting in a GOR of C. Neither one of these
cases had seizures, resulting in a GOR of N for ASD and seizures.
Seizures and neurological symptoms have been shown to improve
with standard therapy in individuals with urea cycle disorder in
large cohort (Level 2b) and case series (Level 4) studies resulting
in a GOR of B (141).
SUCCINIC SEMIALDEHYDE DEHYDROGENASE DEFICIENCY
Succinic semialdehyde dehydrogenase deficiency is a rare autoso-
mal recessive disorder of GABA metabolism that includes ASD
features and seizures (142). In the absence of succinic semialde-
hyde dehydrogenase, GABA is degraded by an alternative pathway
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that produces gamma-hydroxybutyric acid. Vigabatrin inhibits the
formation of succinic semialdehyde but has been inconsistent in
the control of seizures and cognitive improvement, resulting in a
GOR of D – NE for inconsistent result (142).
CREATINE DEFICIENCY SYNDROMES
Creatine and phosphocreatine play important roles in energy stor-
age and transmission of high-energy phosphates. Three inborn
disorders of creatine metabolism, collectively known as the cre-
atine deficiency syndromes, include symptoms of developmental
delay, regression, ASD features, mental retardation, language dis-
orders, dyskinesia, and seizures (143). Several case series (Level
4) and case reports (Level 4) have documented that creatine defi-
ciency disorders can be treated with high doses of creatine mono-
hydrate along with restriction and supplementation of specific
amino acids (GOR of C) (141).
BIOTINIDASE DEFICIENCY
Disorders of biotin (vitamin B7) metabolism manifest with
seizures and developmental delays. One child with ASD has
been reported to have a partial biotinidase deficiency but did
not respond to biotin supplementation (Level 4). However, the
younger brother who also manifested symptoms of partial bio-
tinidase deficiency did not develop ASD potentially due to treat-
ments started early in life (Level 4) (144). Biotin supplementation
has not been documented to improve seizures in biotinidase defi-
ciency (141). Thus, biotin receives a GOR of D – NE for a neutral
effect on seizures, ASD symptoms, and seizures in ASD.
SMITH–LEMLI–OPITZ SYNDROME
Many (50–75%) children with Smith–Lemli–Opitz syndrome
meet criteria for ASD (145, 146). Treatment with cholesterol sup-
plementation in children with Smith–Lemli–Opitz syndrome has
been reported to improve ASD and associated behavioral symp-
toms in a case report (147) (Level 4), case series (148) (Level 4),
and prospective cohorts (149, 150) (Level 2a), especially in young
children (151), although a short DBPC trial (Level 2b) in mostly
children and adolescents did not confirm such findings (152).
Thus, cholesterol supplementation receives a GOR of B for young
children with Smith–Lemli–Opitz syndrome for behavioral ASD
symptoms. Cholesterol supplementation has not been studied for
seizure control for Smith–Lemli–Opitz syndrome in children with
or without ASD resulting in a GOR of N.
BRANCHED-CHAIN KETOACID DEHYDROGENASE KINASE DEFICIENCY
Inactivating mutations in the branched-chain ketoacid dehydro-
genase kinase gene were identified in two consanguineous fam-
ilies with ASD, epilepsy, and intellectual disability. This muta-
tion resulted in reduced levels of branched-chain amino acids.
Treatment with a diet enriched in branched-chain amino acids
resulted in reversal of neurological abnormalities in the mouse
model (Level 5) and normalization of amino acids without clinical
improvement in a case series of patients (Level 4) with this muta-
tion (153). Interestingly, one study of genetic absence epilepsy rats
from Strasbourg, a genetic model of generalized non-convulsive
epilepsy (Level 5), reported increased seizures with an intraperi-
toneally injection of branched-chain amino acids, presumably due
to the role of these amino acids on glutamate metabolism (154).
Thus, dietary enrichment of amino acids probably should not
be used in epilepsy in general because of the possible detrimental
effects (GOR of D – PD for possible detrimental), and only be care-
fully considered in the context of known branched-chain ketoacid
dehydrogenase kinase deficiency as the evidence for improvement
on ASD symptoms and/or epilepsy is lacking and not consistent
with the animal model (GOR of D – NE for inconsistency).
PYRIDOXINE-DEPENDENT AND PYRIDOXINE-RESPONSIVE SEIZURES
Pyridoxine is a cofactor for over 110 enzymes. Pyridoxine is
effective for treating children with pyridoxine-dependent or
pyridoxine-responsive seizures (155–158). The effectiveness of
pyridoxine in pyridoxine-dependent and pyridoxine-responsive
seizures has been documented in many case studies (Level 4)
(159), resulting in a GOR of C. When pyridoxine-dependent and
pyridoxine-responsive seizures are suspected, it is important to
remember that pyridox(am)ine phosphate oxidase deficiency and
neonatal/infantile hypophosphatasia are in the differential diagno-
sis and that co-treatment with folinic acid and a lysine restricted
diet should also be considered (159).
The notion of abnormal pyridoxine metabolism was first sug-
gested when a subset of children with ASD were found to have
abnormalities associated with pyridoxine-dependent enzymes on
a tryptophan loading test (160). Several open-label trials demon-
strated positive results for vitamin B6 (161, 162). For example,
in a large open-label (Level 2b) study, children with ASD were
shown to have global improvement with a vitamin combina-
tion that included high dose (150–450 mg) pyridoxine (162). A
small randomized DBPC cross-over variable-dose (75–3000 mg)
withdrawal study (Level 2b) demonstrated that significantly more
children with ASD demonstrated improvement on pyridoxine
(73%) as compared to the placebo (20%) (163). A DBPC cross-
over trial (Level 2b) which evaluated pyridoxine as well as several
other treatments for ASD symptoms did not demonstrate efficacy
of pyridoxine as compared to baseline (164). However, this latter
study may have been flawed since it did not compare the only pyri-
doxine group to placebo. Thus, pyridoxine receives a GOR of B for
treatment of behavioral and cognitive ASD symptoms. However,
there is larger support for the use of pyridoxine in combination
with magnesium to treat ASD symptoms (see section below).
To date, there has been one case report of ASD associated with
severe mental retardation, aerophagia, breath holding, self-injury
and pyridoxine-dependent seizures (165). According to this report,
high-dose pyridoxine improved seizures but it was not possible to
measure whether it improved ASD characteristics (Level 4), there-
fore pyridoxine receives a GOR of D – SC for treatment of seizures
in individuals with ASD.
ABNORMALITIES IN COBALAMIN METABOLISM
Cobalamin deficiency is uncommonly associated with seizures
(166, 167), with the most common presentation including mega-
loblastic anemia, feeding difficulties, developmental delay, micro-
cephaly, failure to thrive, hypotonia, lethargy, irritability, invol-
untary movements, and cerebral atrophy. Seizures may be focal,
multifocal, and/or myoclonic (166, 167), may develop after treat-
ment starts (166) and have been documented to improve with
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cobalamin supplementation in many case reports (Level 4) (166,
167). Thus, cobalamin supplementation for seizures in the context
of cobalamin deficiency receives a GOR of C.
Children with ASD have been shown to have abnormalities in
cobalamin (vitamin B12) dependent metabolism (117). A recent
prospective open-label study (Level 2b) demonstrated that glu-
tathione, but not methylation, metabolism could be improved in
children with ASD following a 3-month supplementation with
methylcobalamin injection and oral folinic acid (168). This study
did not report the effects of the therapy on ASD cognition or
behavior, but a small, prospective, open-label study (Level 2b)
demonstrated significant improvements in core ASD symptoms
as well as intelligence and developmental quotient with methyl-
cobalamin injections (169). Thus, cobalamin receives a GOR of C
for treatment of behavioral and cognitive abnormalities in ASD
and a GOR of N for seizures in individuals with ASD since there
are no supporting studies.
ORGANIC ACIDURIAS
Although several organic acidurias have been reportedly associ-
ated with ASD in case studies, including d-glyceric aciduria (170),
propionic acidemia (171), and l-2-hydroxyglutaric aciduria (172),
only d-glyceric aciduria has been associated with seizures (170). In
this latter case report, seizures and ASD symptoms improved with
fructose restriction (170). Since the use of fructose restriction has
only been reported in this one case, this therapy receives a GOR of
D – SC for treatment of ASD symptoms and seizures and a GOR of
N for epilepsy as there are no studies supporting such a treatment.
In addition, since such therapy is specific to a particular organic
aciduria, it is unlikely to be a candidate as a novel therapy for the
treatment of epilepsy in ASD or other metabolic disorders.
NOVEL TREATMENTS
Considering the wide use of novel treatments in the ASD popu-
lation (10, 11, 173), a discussion of such treatments as adjunctive
therapy in seizure control deserves consideration. Here we review
some of the more commonly used novel therapies in ASD that
have some evidence for treating seizures.
MAGNESIUM (MG)
Ionized Mg (Mg2+) has antagonistic effects on the N -methyl-d-
aspartate receptor (174, 175) and magnesium deficiency may be a
factor in several forms of epilepsy (176–178). It has been suggested
that low Mg2+ or altered balance between Mg2+ and ionized cal-
cium (Ca2+) may precipitate seizures (179). Patients with epilepsy
have been shown to have significantly lower mean Mg2+ levels and
an increased Ca2+/Mg2+ ratio in spite of normal total serum Mg
levels (180). Mg has been shown to decrease the seizure duration
in idiopathic epilepsy with the reduction in duration proportional
to the severity of the seizure (181).
A review of controlled trials (Level 1a) of Mg sulfate (MgSO4)
use for the prophylaxis and management of eclamptic seizures
demonstrated its overwhelming evidence as the standard of care
(182). In a small, open-label study (Level 2b) on infantile spasms,
adding MgSO4 to ACTH resulted in improvement in the resolu-
tion of seizures (183). A small, retrospective, chart review (Level 4)
suggested that adjunctive oral Mg treatment resulted in substan-
tial improvement in seizure frequency in patients with refractory
epilepsy (184). Based on case series, Mg has been recommended as
second line therapy in status epilepticus in an expert review (Level
5) (185) and has been reported to be therapeutic in the treatment
of refractory status epilepticus in two girls with juvenile-onset
Alpers’ syndrome (Level 4) (186). The significant evidence for Mg
as a treatment for seizures results in a GOR of A.
In children with ASD, Mg in combination with pyridoxine is
used as a novel treatment, and Mg alone is used for the treatment
of constipation but has undergone few clinical studies. In one
DBPC cross-over study (Level 2b), a comparison between Mg and
placebo demonstrated mixed results in treatment of ASD symp-
toms (164). Given the mixed results, Mg receives a GOR of D – NE
for inconsistent results for the treatment of ASD symptoms. Mg
supplementation has not been investigated in children with ASD
who have epilepsy resulting in a GOR of N. However given that it
is helpful in other conditions with seizures, it has the potential to
help children with ASD who also have seizures.
COMBINED PYRIDOXINE AND MAGNESIUM THERAPY
An early study suggested positive behavioral effects of combined
pyridoxine and Mg in children with ASD in a moderately sized,
open-label, study (Level 2b) (187). In a hybrid designed study,
about 34% of 44 ASD children were found to be responders in a
initial open-label phase study with their response verified in an
subsequent DPBC phase (Level 2b) (188). In a rather complicated
medium-size DBPC cross-over design (Level 2b), the combination
of pyridoxine and Mg was shown to be superior to each treatment
alone and to placebo (164). However, more recent small DBPC
studies (Level 2b) have not identified an effect of either high-dose
(189) or low-dose (190) combination therapy for children with
ASD. A recent uncontrolled (Level 4) study demonstrated that
the combination of pyridoxine, Mg, and riboflavin significantly
reduced the levels of urine dicarboxylic acid in children with ASD
(191). Combination pyridoxine and Mg therapy has not been used
in epilepsy in children with or without ASD, although each com-
ponent alone has been used (see above). Thus, for epilepsy with
or without ASD, this combination receives a GOR of N. A recent
review of novel therapies for use in ASD did suggest that this com-
bination therapy was acceptable with careful monitoring (173)
and given the studies reviewed above, the combination receives a
GOR of B for cognitive and behavioral symptoms in ASD. Given
that these therapies might have benefit effects in selected children
with ASD and epilepsy, the combination therapy may be beneficial
and should undergo further research.
ZINC
Two recent studies have demonstrated that plasma zinc (Zn) is
reduced in children with ASD (192, 193), while two other stud-
ies have not supported such findings (194, 195). Zn is essential
for immune, hormone, antioxidant, genetic, neurological, and
physiological processes. Low Zn has been found in the serum
and cerebrospinal fluid of children with febrile seizures in case-
control studies (196, 197) and was associated with adult epilepsy
in one case-control study of 40 patients and matched healthy con-
trols (198) and also with idiopathic intractable epilepsy in one
case-control study of 70 participants matched on age, ethnicity,
and socioeconomic status (199). Although Zn has been shown
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to decrease the duration of excitatory response of dentate gran-
ule cells derived from patients with medial temporal lobe epilepsy
(Level 5) (200) and decrease seizure susceptibility in the EL mouse
model (Level 5) (201), it has not undergone any clinical trials as
a treatment for epilepsy. Thus, it receives a GOR of D – BR for
treatment for seizures because the evidence is based on only bench
research. Although there is no evidence to support Zn supple-
mentation in the treatment of epilepsy in ASD or for improving
behavior and cognition in ASD (GOR of N), given the important
role of Zn in neuronal function, the supportive laboratory data,
and the fact that children with ASD might already have a defi-
ciency, Zn supplementation may be an important novel treatment
to investigate in the future.
DIMETHYLGLYCINE
There have been mixed reports of effectiveness of dimethylglycine
(DMG) on seizures. In a single-subject repeated-measures design
(Level 4), a significant reduction in seizures in a 22-year-old male
with mental retardation and intractable epilepsy was reported with
the use of 90 mg of DMG twice daily (202). However, small clin-
ical trials have not verified the efficacy of DMG. No reduction in
seizure frequency was found in five participants with refractory
seizures given 270 mg of DMG/day over a 1-month period in a
DBPC cross-over study (Level 2b) (203). No reduction in seizure
frequency was found between the control and treatment groups in
a DBPC study of 20 patients with mental retardation and seizures
treated with 300 mg of DMG/day during the first 2 weeks of the
study, and then 600 mg/day during the second 2 weeks of the study
(Level 2b) (204). DMG receives a GOR of D – NE for inconsistent
evidence for the treatment of seizures. DMG has been evaluated in
two small DBPC (Level 2b) for children with ASD, both of which
demonstrated no significant benefit for ASD symptoms (205, 206).
DMG receives a GOR of D – NE for inconsistent evidence of effec-
tively treating ASD symptoms. DMG has not been studied in a
controlled fashion in children with ASD and seizures so it receives
a GOR of N. This evidence does not support further investigation
of DMG as a novel treatment in individuals with ASD and seizures.
TAURINE
Taurine is a sulfur containing organic acid that may have neu-
roprotective and neuromodulating properties. Taurine has been
proposed to be a weak GABAA and GABAB receptor antagonist
with potential anticonvulsant activity (207–211) but its ability to
cross the blood-brain barrier is limited (212) and studies have not
been conducted to determine if taurine could be an efficacious
therapy for epilepsy (213). Two studies found that plasma taurine
levels were significantly lower in children with ASD compared
to controls (195, 214) while another study reported that taurine
improved learning in Fragile X mice (215). Taurine has been stud-
ied in two open-label treatment studies of children and adults with
drug-resistant epilepsy without a noted sustained beneficial effect
(Level 2b) (216, 217) while two open-label studies of taltrimide,
a taurine derivative, demonstrated no clinical effect in one study
and a proconvulsive effect in the other study (Level 2b) (218, 219).
Thus, taurine receives a GOR of D – PD for having possible detri-
mental effects for the treatment of seizures. The effect of taurine
on children with ASD and epilepsy has not been systematically
studied resulting in a GOR of N. Given the fact that it has not
been found to be effective in children with epilepsy, there is little
support for its use in children with ASD and epilepsy.
CARNOSINE
Carnosine (B-alanyl-l-histidine), a naturally occurring dipeptide,
not only serves as a source of histidine, a precursor of histamine
(220, 221), but unlike histamine, it is able to cross the blood-
brain barrier. l-Carnosine has been demonstrated to significantly
improve the Gilliam Autism Rating Scale and the Receptive One-
Word Picture Vocabulary tests without any adverse effects in an
8-week DBPC study in children with ASD (Level 2b) (222). With
only one Level 2b study, l-carnosine receives a GOR of C for the
treatment of cognitive and behavioral symptoms of ASD.
Histamine’s involvement in mechanisms regulating seizure sus-
ceptibility has been documented in multiple studies (223–225).
Focal introduction of histamine or histidine within the central
nervous system increases seizure threshold in animal seizure mod-
els (Level 5) (224, 226–228). Carnosine has been shown to have an
anticonvulsant effect in several animal models of seizures (Level
5) (228–231), thus it receives a GOR D – BR for evidence based on
bench research. l-Carnosine has not been evaluated in children
with ASD and seizures, so it receives a GOR of N. l-Carnosine
appears well tolerated and has the potential to improve both ASD
symptoms and seizures, so it may be a promising therapy for
individuals with ASD and seizures.
OMEGA-3 FATTY ACIDS
Several studies have demonstrated a protective effect of omega-3
fatty acids, particularly, docosahexaenoic acid, in animal models
of epilepsy (232), creating enthusiasm for their use in humans,
especially because of their positive effect on cardiovascular health
(233). An early DBPC study (Level 1b) suggested that the effect
of omega-3 fatty acids on seizures was transient (234) while more
recent small open-label (235) and DBPC (236) studies (Level 2b)
suggest a trend toward seizure improvement in individuals with
refractory epilepsy. However, another DBPC study (Level 2b) did
not confirm this finding (237) in refractory epilepsy. Interestingly,
one small DBPC study (Level 2b) in individuals with refractory
epilepsy demonstrated significant improvements in parameters of
cardiovascular health, particularly in improvement in an index of
sudden unexplained death in epilepsy (236) while another small
DBPC study (Level 2b) of patients with refractory epilepsy that
used magnetic resonance spectroscopy demonstrated a reduc-
tion in membrane phospholipid breakdown and improvement in
energy metabolism in the brain (238). Thus, omega-3 fatty acids
receive a GOR of C for the treatment of epilepsy.
Several studies have noted that essential fatty acids are abnor-
mal in individuals with ASD (239–242). Several small clinical
studies have examined the effect of omega-3 fatty acids in chil-
dren and adults with ASD. Two open-label studies (Level 2b)
demonstrated improvements in ASD symptoms (243, 244) while
no significant effects could be found in other open-label stud-
ies (Level 2b) on adults or children with ASD (245, 246). Two
DBPC studies (Level 2b) demonstrated non-significant behavioral
improvements in hyperactivity (247, 248) and stereotyped behav-
ior (247) in individuals with ASD. Thus, the evidence for use of
omega-3 fatty acids in ASD remains promising, resulting in a GOR
of B. Omega-3 fatty acids have not been evaluated in children with
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ASD and seizures, so it receives a GOR of N. However, it remains
a promising novel treatment.
HOMEOPATHY
Homeopathy uses extremely dilute solutions of active agents to
stimulate immune defenses and normalize homeostatic mecha-
nisms. In contrast, the allopathic approach uses high doses of
agents to directly attack microorganisms or to block systemic
reactions. Homeopathy is viewed skeptically because the main
ingredients in its remedies are diluted out of material existence.
For example, homeopathic remedies are diluted, at times, beyond
Avogadro’s limit, making it unlikely that even one molecule of
the agent is in solution. Analysis of homeopathic agents showed
both quantitative and qualitative differences from controls using a
variety of scientific measures, including ultraviolet spectroscopy,
Raman spectroscopy, and thermodynamics (249, 250). These data
are used to support the controversial hypothesis that succussion, a
process used in the preparation of homeopathic remedies, poten-
tiates biological activity of the solution by generating surrogate
structured water domains with biologic activity (49, 251). While
older meta-analyses conclude that the clinical effects of home-
opathy could not be completely accounted for by a placebo effect
(252, 253), a recent meta-analysis that compared homeopathic
and allopathic placebo-controlled trials suggested that the weak
effects found in homeopathy studies is consistent with a placebo
effect (254).
Evidence for the effectiveness of homeopathy treatment for
attention-deficit disorder has been documented in a randomized
DBPC cross-over trial (Level 1b) (255) suggesting an applica-
tion to children with ASD. Although several case reports (Level
4) have suggested that homeopathy therapy could be useful in
the treatment of epilepsy (256, 257), inconsistency in the home-
opathic compounds used and the lack of a temporal relationship
between the initiation of homeopathy treatment and the resolu-
tion of seizures in these reports limits the strength of this evidence.
In addition, the only homeopathy study in ASD reported worsen-
ing of behavior with treatment (258). Thus, it receives a GOR of
N for epilepsy as the current case reports are too low in qual-
ity to conclude anything in particular and a GOR of D – PD for
possibly being detrimental in ASD. Since it has not been stud-
ied in individuals with ASD and seizures, it receives a GOR of N.
Thus, homeopathy does not appear to be a promising treatment
for epilepsy and may be detrimental in ASD.
DIET
Many children with ASD are treated with various diets, including
the gluten-free casein-free (GFCF) and elimination diets such as
the Feingold diet. Each will be discussed separately.
The GFCF diet has received considerable attention in ASD
treatment. A recent two-stage 24-month randomized single-blind
controlled trial (Level 1b) has provided support for the GFCF diet
(259), yet a relatively brief (12-weeks) DBPC cross-over treatment
trial (Level 1b) of the GFCF diet did not demonstrate evidence of
objective efficacy despite parental reports of effectiveness (260). In
a retrospective, controlled survey study (Level 3b) children with
gastrointestinal symptoms, food allergies, and/or sensitivities or
those who strictly adhered to the diet, parents rated the GFCF
diet as significantly improving ASD behaviors,physiological symp-
toms, and social behaviors as compared to children without these
disorders or in which the diet was implemented with many infrac-
tions (261). Thus, for ASD symptoms the GFCF diet receives a
GOR of B.
A recent case report (Level 4) demonstrated that the GFCF diet
combined with the KD significantly improved seizures in a 12-
year-old girl with ASD (44). In a recent case-control survey (Level
3b) of treatments for seizures in children with ASD, parents rated
the GFCF diet as a treatment with favorable effects on seizures and
other symptoms (Figure 2) (10). The GFCF diet has not been eval-
uated for epilepsy in individuals without ASD although one report
suggests that gluten sensitivity is associated with hippocampal scle-
rosis in temporal lobe epilepsy (262). Thus, for the treatment of
seizures, the GFCF diet receives a GOR of C for ASD individuals
and GOR of N for individuals without ASD. One interesting con-
nection between the GFCF diet and seizures is that the GFCF diet
is a milk-free diet and a milk-free diet can reduce the serum titer of
the FRα autoantibody (see Abnormalities in Folate Metabolism).
The Feingold diet eliminates food additives and therefore is
believed to reduce the excitatory-inhibitory balance of the brain
(263). A recent systematic review and meta-analysis suggests that
artificial food coloring exclusion could have a role in the treatment
of attention-deficit hyperactivity disorder (Level 1a) (264), thus
supporting the role of the Feingold diet in some neurodevelop-
mental disorders. The Feingold diet was shown to improve seizures
using a single-subject design in a child with TSC not reported to
have ASD (Level 4) (263) but has not undergone any additional
study on individuals with seizures, epilepsy, or ASD. Thus, the
Feingold diet receives a GOR of D – SC for seizures and GOR of
N for individuals with ASD with or without seizures.
Clearly, additional controlled clinical trials are needed to docu-
ment the efficacy of these promising areas of dietary intervention.
Dietary interventions are an important area of research, espe-
cially since many parents implement dietary intervention on their
own and little objective evidence is available to provide parents
guidance on these diets.
TRANSCRANIAL MAGNETIC STIMULATION
Repetitive transcranial magnetic stimulation (rTMS) is a non-
invasive technique for manipulating the electrophysiological activ-
ity of the cortex and has potential for the study, diagnosis, and
treatment of ASD and seizures (Figure 3) (265). Low-frequency
(“slow”) rTMS (in the 0.3- to 1-Hz frequency range) which pref-
erentially activates radially oriented, double-bouquet axons, and
other inhibitory interneuronal elements has been proposed to
operate via long-term depotentiation and depression of cortical
activity (266). It is suggested that the application of slow rTMS over
the dorsolateral prefrontal cortex of ASD patients may strengthen
the inhibitory surrounding minicolumns in this cortical area (267,
268). The rational for using rTMS is based on studies suggesting
a minicolumnopathy in ASD resulting in a deficit in cortical inhi-
bition (269, 270). Although rTMS has never been used to treat
seizures or epilepsy in ASD, there are several studies that have
examined its use in the treatment of ASD symptoms and in the
treatment of seizures separately. In individuals with ASD, low-
frequency rTMS has been shown to improve error monitoring
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FIGURE 3 |The transcranial magnetic stimulator. A block diagram
depicting the transcranial magnetic stimulator circuit is depicted on the left.
The power supply charges the capacitor. An operator or computer then
signals for the charge stored in the capacitor to be released into the
stimulation coil through a thyristor switch. The current flowing through the
stimulating coil (here depicted as a circular coil) produces a perpendicular
magnetic field which transverses the skull and induces electrical currents
within the cortex underlying the coil.
(271), event-related gamma (267), and repetitive-ritualistic behav-
iors (267) in two small open-label controlled trials (Level 2b) and
to improve event-related potentials related to novelty stimuli in
a small open-label uncontrolled trial (Level 2b) (268). Thus, it
receives a GOR of B for the treatment of ASD. Three random-
ized, DPBC studies have examined the effect of low-frequency
rTMS for the treatment of epilepsy in adult patients (Level 2b).
While only one study demonstrated a significant reduction in
seizures (272) another study demonstrated borderline significance
for seizure reduction (273), while the third demonstrated a signif-
icant decrease in epileptiform abnormalities in one-third of the
patients (274). A decrease in epileptiform discharges using low-
frequency rTMS was confirmed in another more recent case series
(Level 4) (275). Thus, it receives a GOR of B for the treatment of
epilepsy. Since slow rTMS has not been studied in individuals with
ASD and epilepsy, it receives a GOR of N. Clearly low-frequency
rTMS is a promising novel treatment for both epilepsy and ASD
and should undergo larger DPBC studies to further investigate its
therapeutic effect.
SUMMARY
This review aimed to outline the evidence for the use of traditional
and novel treatments for seizures in individuals with ASD. Using
a standardized scale, Table 3 presents the evidence for using these
treatments to improve seizures in general, to improve the behav-
ioral and cognitive symptoms associated with ASD, and to improve
seizures specifically in individuals with ASD. One of the most obvi-
ous conclusions from this review is that few treatments for seizures
have been specifically evaluated in individuals with ASD. Specific
genetic (93), metabolic (276), and immunologic (276) abnormal-
ities as well as cortical hyperexcitability (277) are believed to be
associated with ASD. All of these abnormalities could also drive the
development of seizures and epilepsy in ASD individuals. Thus, it
is important to determine whether specific treatments that address
these pathophysiological mechanisms are effective treatments, as
such treatments may improve seizures while also improving, or at
least not worsen, core symptoms of ASD.
ANTI-EPILEPTIC DRUG TREATMENT FOR SEIZURES IN AUTISM
SPECTRUM DISORDER
There are no well-controlled clinical trials which examine the
effectiveness or efficacy of AEDs for the treatment of seizures in
individuals with ASD, despite the fact that this issue has been
pointed out almost a decade ago (278). There is good reason to
believe that certain AEDs might be more appropriate for certain
individuals with ASD. AEDs can cause neurological adverse effects
(e.g., ataxia, tremor, and nystagmus), gastrointestinal adverse
effects (e.g., abdominal pain and nausea), and allergic reactions.
Since adverse effects of AEDs tend to be more frequent in chil-
dren with developmental disabilities, AEDs with greater risk of
adverse effects might limit their usefulness in treating children
with ASD (279). In addition, prolonged treatment with AEDs,
especially older AEDs, can cause memory and/or attention deficits
as well as somnolence, psychomotor abnormalities, and dizzi-
ness (280). Alternatively, ASD may be associated with cortical
hyperexcitability, potentially due to deficits in cortical inhibitory
circuits or glutamate receptor abnormalities (277, 281, 282). Thus,
AEDs that enhance γ-aminobutyric acid (GABA) signaling, such
as valproate, gabapentin, clobazam, clonazepam, phenobarbital,
primidone, tiagabine, or vigabatrin, might be relatively better
treatments for individuals with ASD. Lastly, since individuals with
ASD appear to have a wide range of seizure types, broad-spectrum
AEDs, such as valproate, lamotrigine, or levetiracetam might be
optimal treatments.
From the above literature review, it appears that there is only
limited evidence to guide the selection of specific AEDs for treat-
ing seizures in ASD, although the limited evidence does appear
to be consistent across studies. The majority of studies on AEDs
in ASD have reported data primarily on three AEDs, valproate,
lamotrigine, and levetiracetam. Some studies have also reported
the use of phenytoin, carbamazepine, ethosuximide, topiramate,
oxcarbazepine, gabapentin, and phenobarbital in individuals with
ASD. Overall, studies suggest that broad-spectrum AEDs, specif-
ically valproate, lamotrigine, and levetiracetam, appear to be the
most effective and have a low rate of cognitive and neurological
adverse effects. Therefore, these may be the most appropriate pri-
mary AEDs to start in individuals with ASD and clinical seizures.
We will briefly discuss these AEDs below.
Valproate is a broad-spectrum AED which has been docu-
mented to have positive behavioral effects in several DBPC studies,
has been associated with improvement in core ASD symptoms in
case reports and in an open-label trial and, at therapeutic doses,
has little adverse effects on cognition (283). Yet it requires mul-
tiple blood tests, can deplete carnitine and can result in serious
adverse effects, including hepatotoxicity, hyperammonemia, and
pancreatitis. l-Carnitine has been shown to decrease the hyper-
ammonemia in patients with valproate-induced encephalopathy
and is recommended in severe valproate poisoning. Co-treatment
with l-carnitine is recommended for high-risk pediatric patients
receiving valproate (284, 285). Given that children with ASD are at
high risk for mitochondrial dysfunction and, as a group, generally
have low carnitine levels (107, 286), and that carnitine deficiency
may be a risk factor for developing valproate hepatotoxicity (287,
288), it is probably wise to start l-carnitine supplementation when
prescribing valproate to individuals with ASD especially if they
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consume little beef or pork, the primary dietary sources of carni-
tine. The recommended oral dose varies from 30 to 100 mg/kg/day
in two to three daily divided doses for high-risk individuals such
as young children or those who have carnitine deficiency (284).
Thus, it is probably wise to use care when prescribing valproate in
children with ASD and monitor carnitine levels during treatment.
However, the fact that valproate is reported to be well tolerated
and considerably beneficial in many studies examining the ASD
population specifically is reassuring.
Lamotrigine is another broad-spectrum AED that is believed
to have minimally adverse effects on cognition in individuals with
epilepsy (36) and may have beneficial effects on core ASD symp-
toms (17), or at least not worsen behavior or ASD symptoms (35).
The use of lamotrigine as a first-line AED needs to be balanced
with the prolonged time required for titration to a therapeutic
dose in order to minimize the unlikely but serious adverse effect
of a Stevens–Johnson reaction.
Levetiracetam is a relatively broad-spectrum AED that has min-
imal liver metabolism with a low incidence of serious adverse
effects. The most common adverse effect of levetiracetam in the
general population is behavioral, including agitation, aggressive
behavior, and mood instability. However, it is reassuring that a
DBPC trial suggests that there is no change in aberrant or repeti-
tive behaviors or impulsivity or hyperactivity in children with ASD
treated with levetiracetam (34). If behavioral adverse effects arise,
they may be mitigated with pyridoxine. Major et al. (289) treated
patients on an average dose of 63 mg/kg/day of levetiracetam with
an average of 6 mg/kg/day of pyridoxine if behavioral problems
developed after starting levetiracetam. Of the 22 patients treated,
41% improved, 36% demonstrated no change, and 18% became
worse. Improvement in levetiracetam associated behavior abnor-
malities with pyridoxine treatment was also reported in one case
study (290). Since pyridoxine clearly does not work in all cases and
since levetiracetam does not appear to cause significant behavioral
problems in ASD in controlled studies (34), it is probably best to
use pyridoxine on an as needed basis. It is also important to be
aware that many children with ASD may already be on a form of
pyridoxine as a novel therapy (10). In addition, this review suggests
that the combination of pyridoxine with Mg may be more effective
for behavior in children with ASD than either one alone, so it may
be wise to add Mg to pyridoxine treatment. Levetiracetam has an
intravenous and liquid formulation, so it can be titrated quickly,
provided to individuals that cannot take medication orally, and
given to children who cannot swallow pills.
Mitochondrial disease and dysfunction are prevalent in indi-
viduals with ASD (106, 107, 276, 286), and certain AEDs may be
more appropriate for individuals with mitochondrial abnormal-
ities. Some worry about the use of valproate in ASD given its
potentially devastating effect on children with specific MDs. It is
important to understand that this detrimental effect is isolated to
individuals with POLG1 mutations and myoclonic epilepsy with
ragged red fibers syndrome (291). POLG1 mutations have only
been reported in two children with ASD, or 2% of ASD chil-
dren reported to have MD, and myoclonic epilepsy with ragged
red fibers has not been reported to date in individuals with ASD
(107). Given that approximately 5% of children with ASD have
classically defined MD, the estimated prevalence of the POLG1
mutation is therefore approximately 0.1% of the ASD population.
One study has examined the effect of common AEDs, including
phenobarbital, carbamazepine,and lamotrigine,on mitochondrial
function. While carbamazepine showed a detrimental effect on
mitochondrial function with chronic use, lamotrigine was found
to enhance mitochondrial function (292). Other in vitro studies
have also demonstrated that lamotrigine is mitochondrial protec-
tive (293). Thus, there is little evidence to guide the understand-
ing of optimal AED treatments for children with mitochondrial
abnormalities with and without ASD. However, given that lamot-
rigine appears to be well tolerated in individuals with ASD and
may have positive effects on mitochondrial function, at least in
preliminary studies, lamotrigine may be the optimal AED for chil-
dren with ASD and MD. This is indeed a ripe area for clinical
research.
Overall, the data reviewed above supports the use of valproate,
lamotrigine, and levetiracetam as the first-line treatments in chil-
dren with ASD who have seizures or epilepsy. Table 4 outlines
some guidelines that might be helpful for choosing first-line AEDs.
Clearly more research is needed to document the efficacy of AEDs
in the ASD population.
TRADITIONAL NON-ANTI-EPILEPTIC DRUG TREATMENT FOR SEIZURES
IN AUTISM SPECTRUM DISORDER
Several traditional non-AED treatments for seizures were
reviewed, specifically the KD and MAD, theVNS, standard epilepsy
surgery and MST, immunomodulatory therapy, and neurofeed-
back. Overall, many of these therapies, except for standard epilepsy
therapy (i.e., cortical resection) and the VNS, appear to have
promising applications for the treatment of seizures in children
with ASD.
The KD and MAD may be useful for treating several aspects of
ASD, especially in individuals with ASD with seizures and/or MD.
Indeed, recently there has been increased interest in using these
diets in ASD (294–297). The KD may be an effective treatment for
MD (298–300) and has been recommended for individuals with
co-occurring MD and epilepsy (301). Given that individuals with
ASD and co-occurring MD have high rates of seizures (107), the
KD and MAD should be strongly considered in the subgroup of
individuals with ASD and co-occurring MD. In addition, given
the excellent safety profile of the KD and MAD as well as stud-
ies which suggest their effectiveness in drug-resistant epilepsy and
their tolerability in ASD, the KD and MAD should be considered
in children with ASD who have epilepsy that is refractory to stan-
dard treatments. Of course, children should be carefully monitored
when the KD is started as the diet can worsen the metabolic acido-
sis associated with mitochondrial or other metabolic disorders and
should be managed by a practitioner experienced with these diets.
Table 4 | Guidelines for selecting a first-line antiepileptic drug for
children with autism spectrum disorder.
ASD symptoms Avoid Possible alternative
Gastrointestinal disorders Valproate Levetiracetam, lamotrigine
Mitochondrial disorders Valproate Levetiracetam, lamotrigine
Poor growth Topiramate Lamotrigine
Overweight Valproate Lamotrigine, levetiracetam
Behavioral problems Levetiracetam Valproate
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Although standard epilepsy surgery may be helpful for control-
ling seizures, there does not appear to be good evidence supporting
the notion that standard epilepsy surgery improves cognition or
symptoms associated with ASD, and there are many cases in which
standard epilepsy surgery has worsened these factors. Several case
series have suggested that MST may improve both seizures and
ASD related symptoms. Impressive outcomes have been demon-
strated in one study in which children underwent extensive elec-
trophysiological study and had careful surgically treated foci with
MST. However, MST requires more extensive study before it can
be routinely used as a treatment option for children with ASD who
have refractory epilepsy.
Given the growing literature on immune dysregulation in ASD
(276), it would not be surprising if immunomodulatory treat-
ments would be useful in children with ASD and seizures. There
are promising studies for the use of both IVIG and steroids for
the treatment of epilepsy, ASD related symptoms, and seizures in
individuals with ASD,although none of these studies are high qual-
ity. Given that these treatments target specific pathophysiological
mechanisms, the development of clear guidelines for identifying
children with ASD with or without epilepsy who might bene-
fit from such treatment would be helpful, especially given the
potential adverse effect of long-term use of immunomodulatory
therapies such as steroids. Clearly this is an area that is ripe for
further clinical study.
Neurofeedback is an interesting emerging treatment for both
seizures and ASD symptoms that has an excellent safety profile
and has growing evidence for its effectiveness. However, studies
have been limited to particular individuals who could cooper-
ate with the treatment protocol and have underrepresented very
young children and adults as well as lower functioning indi-
viduals and those with more severe ASD symptoms. Because
of the safety of neurofeedback, this may be a promising treat-
ment for children with ASD but further blinded studies would
strengthen the evidence of effectiveness and efficacy for this
therapy.
Thus, several non-AED traditional therapies demonstrate con-
siderable promise in the treatment of seizures in individuals with
ASD, including low-carbohydrate diets such as the KD and MAD,
MST, immunomodulatory therapy, and neurofeedback, although
more research is needed in all of these areas to gain better evidence
for the efficacy and effectiveness of these therapies as well as which
specific ASD subgroups might best respond to these therapies.
Standard epilepsy surgery therapy raises the risk of making ASD
symptoms worse and the VNS has not been shown to improve
ASD symptoms in several studies. Thus, these latter two therapies
should probably be reserved for epilepsy that is refractory to other
epilepsy treatments.
TREATMENTS FOR SEIZURES IN GENETIC AND METABOLIC
SYNDROMES ASSOCIATED WITH AUTISM SPECTRUM DISORDER
This review examined treatments for specific syndromes associ-
ated with ASD and seizures, including genetic syndromes such as
TSC and Fragile X and metabolic disorders such as mitochon-
drial disease and dysfunction, urea cycle disorder, succinic semi-
aldehyde dehydrogenase, branched-chain ketoacid dehydrogenase
kinase, creatine and biotinidase deficiency, Smith–Lemli–Opitz
syndrome, pyridoxine-dependent and responsive seizures, organic
acidemias, and abnormalities of folate and cobalamin metabolism.
Mitochondrial disease and dysfunction and abnormalities in
cerebral folate metabolism are two metabolic abnormalities that
are associated with seizures and appear to affect a substantial
portion of individuals with ASD. Several therapies for these two
disorders have demonstrated effectiveness in the treatment of
symptoms associated with ASD in controlled studies, particular l-
carnitine, multivitamins with antioxidants, N -acetyl-l-cysteine,
and folinic acid. Folinic acid has also been shown to improve
seizures in individuals with seizures and cerebral folate abnormal-
ities in uncontrolled studies. Thus, these treatments may be very
useful for some individuals with ASD and seizures and should be
strongly considered in selected cases.
Evidence also exists for a defect is cobalamin associated metab-
olism in ASD although not for a cobalamin deficiency itself. Still
there is limited evidence that methylcobalamin can improve ASD
symptoms and glutathione metabolism in children with ASD and
other evidence that cobalamin supplementation can be useful in
seizures due to cobalamin deficiency. Because methylcobalamin
appears to be potentially useful for individuals with ASD, this treat-
ment could be useful for those with ASD and seizures, but further
research is needed before such recommendations can be made.
Several case studies have suggested that ASD can occur in spe-
cific metabolic syndromes that have specific treatment. In limited
studies, within the context of the specific syndrome, treatments for
creatine deficiency, d-glyceric aciduria and pyridoxine-dependent
and responsive seizures appear to be helpful for treating seizures,
while treatments for creatine deficiency, d-glyceric aciduria, and
urea cycle disorders appear to be helpful for ASD associated
symptoms. Treatments for biotinidase deficiency, branched-chain
ketoacid dehydrogenase kinase deficiency, and semialdehyde dehy-
drogenase deficiency do not appear to be helpful for ASD symp-
toms or seizures in individuals with ASD, but this is based on
limited reports.
For the two genetic syndromes reviewed, there are no clinically
tested treatments that address the underlying pathophysiological
mechanisms believed to be involved, although bench research is
actively ongoing. For TSC, vigabatrin is the AED of choice for
infantile spasms and seizures starting in infancy and appears to be
most effective when started early in life. For Fragile X, standard
AED therapy appears to be the mainstay at this time. Hopefully
ongoing clinical trials will provide evidence for novel efficacious
therapies that address the underlying pathophysiology of these
syndromes.
This review provides guidance for treatment of seizures in ASD
for specific syndromes and suggests that certain novel treatments,
including l-carnitine, multivitamins with antioxidants, N -acetyl-
l-cysteine, and folinic acid, may be helpful in a wider number of
individuals with ASD and seizures.
POTENTIAL NOVEL TREATMENTS FOR SEIZURES IN AUTISM
SPECTRUM DISORDER
This review examined novel treatments that may have potential
use for individuals with ASD and seizures. Such novel treat-
ments included Mg, pyridoxine and Mg combined, Zn, DMG,
taurine, l-carnosine, omega-3 fatty acids, homeopathy, the GFCF
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and Feingold/elimination diets, and low-frequency repetitive
transcranial magnetic stimulation.
Mg has good evidence as an adjunctive therapy for seizures but
does not have evidence to support its use for ASD associated symp-
toms. However, there is evidence that Mg combined with pyridox-
ine can improve ASD associated symptoms. As neither pyridoxine
nor Mg alone appear to be detrimental to ASD associated symp-
toms and pyridoxine itself can be a treatment for underlying
metabolic deficiencies, the combination of Mg and pyridoxine for
treatment of individuals with ASD and seizures could be a good
treatment to investigate. For an adjunctive treatment for individu-
als with ASD and seizures, Mg is a good candidate, especially since
it can also treat constipation which is a symptom commonly seen
in individuals with ASD, particularly those with mitochondrial
abnormalities.
There has been significant interest in the use of omega-3 fatty
acids for epilepsy and for ASD. Preliminary reports are encourag-
ing but it is clear that the effects are subtle and require larger clinical
samples to obtain statistically significance in clinical studies. One
interesting aspect of this supplement is its potential cardiovascu-
lar benefits in epilepsy patients, specifically improvement in the
index of sudden unexplained death in epilepsy. This is particularly
important as individuals with ASD and epilepsy appear to have
higher rates of unexplained mortality than individuals with ASD
without epilepsy (302).
The GFCF diet appears to be useful in some children with ASD
and has been rated as improving seizures in a controlled survey
study of ASD patients with seizures. Interestingly, a recent case
report has suggested that combining the GFCF diet with the KD
may have some utility in refractory epilepsy in ASD. The GFCF diet
is also a milk-free diet which can decrease the folate-receptor alpha
autoantibody. Thus, the GFCF diet could have some utility for
seizure control in families that are able to implement it, although
controlled studies are clearly needed to determine this possibility.
l-Carnosine has evidence of usefulness in the treatment of ASD
associated symptoms and bench research suggests that carnosine
and its active metabolite may be therapeutic in animal models
of epilepsy. Thus, l-carnosine might be a novel treatment that
has usefulness in the treatment of seizures in individuals with
ASD. In addition, Zn has been shown in bench research to mod-
ulate neuroexcitability and in clinical studies has been found to
be abnormal in individuals with seizures. As Zn abnormalities
have been described in individuals with ASD, this may be a novel
treatment for individuals with ASD and seizures.
Transcranial magnetic stimulation is an emerging treatment
that has shown efficacy in both seizures and ASD symptoms in
limited studies and appears to be safe in children. Although this
treatment requires a relatively cooperative patient, thus limiting
the specific ASD patients in which it is applicable, it might be a
beneficial therapy for selected patients with refractory epilepsy.
Clearly more research and high-quality clinical trials would be
useful to further investigate this therapy.
Certain treatments, such as taurine and homeopathy, have the
potential to be detrimental, at least based on limited evidence,
thus suggesting that they should be generally avoided in individ-
uals with ASD and seizures. In limited studies, DMG does not
appear to be useful for treatment of seizures or ASD symptoms, so
it will probably not be generally useful for the treatment of seizures
in ASD.
Thus, this review suggests that certain novel treatments, such as
Mg with pyridoxine, omega-3 fatty acids, the GFCF diet, and low-
frequency repetitive transcranial magnetic simulation could be
useful for the treatment of seizures and ASD symptoms while other
treatments such as Zn and l-carnosine hold some promise. Other
treatments such as taurine, DMG, and homeopathy are probably
unlikely to be of use.
LIMITATIONS OF PREVIOUS STUDIES AND GUIDELINES FOR FUTURE
STUDIES
Many of the studies reviewed have substantial limitations, partic-
ularly in their approach to documenting the effectiveness of treat-
ments, defining ASD and following improvement in seizures and
ASD symptoms. Few studies are high-quality, controlled, and/or
blinded, and even the high-quality studies have relatively small
populations thus limiting the generalizability of the findings. Many
studies do not have well-defined populations and do not use stan-
dardized tools such as the Autism Diagnostic Observation Sched-
ule or the Autism Diagnostic Interview – Revised to document
the diagnosis of ASD, and other important factors such as lan-
guage and intellectual development are not clearly defined in most
studies. Furthermore, many studies do not quantitatively measure
changes in seizures and many studies use various criteria to define
seizure improvement. There is also a great need for long-term stud-
ies, since many of the treatments are used for years or even decades,
whereas most clinical studies are usually months in duration, and
some of the medications may have long-term adverse effects. Thus,
in the future, promising treatments for seizures in individuals with
ASD must be evaluated in high-quality DBPC studies in order to
establish effectiveness, with long-term follow-up.
CONCLUSION: AN APPROACH TO TREATING CHILDREN
WITH ASD FOR SEIZURES
There are currently no guidelines for the treatment of seizures
in individuals with ASD. Seizures can be treated by a variety
of approaches. Determining the underlying medical etiology of
seizures will assist in directing specific treatment. Many individ-
uals with ASD and seizures could manifest mitochondrial disease
or dysfunction or cerebral folate abnormalities. Identifying and
treating such underlying abnormalities could provide substantial
benefit to the patients and improve seizures. For etiologies without
specific treatments or when an etiological cause cannot be identi-
fied, there appears to be specific AEDs that may be most promising
as first-line treatments, particularly lamotrigine, valproate, and
levetiracetam. Of course, patient characteristics should guide the
AED choice as well as adjunctive treatments to minimize adverse
effects. Promising non-AED treatments, such as the KD and MAD,
may also be particularly useful in ASD individuals with epilepsy.
Some novel treatments such as Mg could theoretically help treat
seizures as adjunctive treatments but they require critical study in
order to be considered for general use in the treatment of seizures
in children with ASD.
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